Citigroup has initiated coverage on Structure Therapeutics (GPCR, Financial) with a "Buy" rating. This development was announced on May 2, 2025, by analyst Samantha Semenkow.
The financial services company has set a price target of $60.00 USD for GPCR. This marks the first time Citigroup has publicly shared an estimated price target for Structure Therapeutics.
Structure Therapeutics focuses on innovative drug discovery and development. With this new coverage, attention on GPCR in the investment community is expected to increase.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 13 analysts, the average target price for Structure Therapeutics Inc (GPCR, Financial) is $80.15 with a high estimate of $118.00 and a low estimate of $50.00. The average target implies an upside of 186.26% from the current price of $28.00. More detailed estimate data can be found on the Structure Therapeutics Inc (GPCR) Forecast page.
Based on the consensus recommendation from 13 brokerage firms, Structure Therapeutics Inc's (GPCR, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
